

Case report**Effect of Temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma**

Luis V. Syro¹, Bernd W. Scheithauer², Leon D. Ortiz³, Camilo E. Fadul⁴, Eva Horvath⁵, Fabio Rotondo⁵, Kalman Kovacs⁵

¹Department of Neurosurgery, Clinica Medellin and Hospital Pablo Tobon Uribe, Medellin, Colombia, ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA, ³Department of Neuro-Oncology, Clinica Las Americas, Medellin, Colombia, ⁴Sections of Hematology, Oncology and Neurology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA, ⁵Department of Laboratory Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada

ABSTRACT

The patient was a 70-year-old man with a recurrent pituitary tumor. Three surgeries were performed but the tumor recurred. Based on histologic, immunohistochemical and ultrastructural studies, the diagnosis of oncocytic gonadotrophic pituitary adenoma was made. The tumor was a macroadenoma partly immunopositive for LH. Immunohistochemistry for O⁶ Methylguanine-DNA Methyl-Transferase (MGMT) showed an admixture of immunopositive and immunonegative cells. After recurrence following operations, the patient was treated with Temozolomide, an imidazotetrazine derivative, DNA-alkylating drug. Following Temozolomide administration the MRI demonstrated significant tumor necrosis. A few months later, the patient died of massive pulmonary embolism. No autopsy was performed. The present case indicates that benign, typically slow-growing pituitary adenomas of oncocytic gonadotrophic type may respond to Temozolomide even when the tumor consists of an admixture of MGMT immunopositive and immunonegative cells.

Key words: MGMT, Neoplasm, Pathology, Pituitary, Temozolomide

INTRODUCTION

Temozolomide is an imidazotetrazine derivative, which methylates DNA at the O⁶ position of guanine, this forming the basis of its utility in the treatment

of gliomas and various neuroendocrine tumors.¹⁻⁴ Recent reports indicate that Temozolomide is efficacious in the therapy of aggressive tumors, including prolactinomas, ACTH-producing adenomas, clinically aggressive adenomas and functioning pituitary carcinomas.⁵⁻¹¹ Herein, we report the favourable effect of Temozolomide in a patient with a large, aggressively growing, albeit benign pituitary adenoma of oncocytic gonadotrophic type. To our knowledge, the effect of Temozolomide on such pituitary adenomas has not yet been investigated in detail.

Address for correspondence:

Bernd W. Scheithauer, M.D., Mayo Clinic, Department of Laboratory Medicine and Pathology, 200 First Street, SW, Rochester, MN 55905, U.S.A., Tel.: 507-284-8350, Fax: 507-284-1599, E-mail: scheithauer.bernd@mayo.edu

Received 13-05-09, Revised 10-07-09, Accepted 03-09-09

CASE REPORT

The patient, a 70-year-old man, had undergone three surgeries for pituitary tumor. The first one in 1989 was followed by radiotherapy. Thereafter, he developed hypopituitarism confirmed by decreased blood hormone levels. Twice thereafter, the tumor recurred, necessitating re-operation in 1999 and 2005. The resected tumor was investigated by histology, immunohistochemistry and transmission electron microscopy. Details of the methods have been described previously.¹²

By light microscopy, the tumor was a chromophobic to slightly acidophilic, PAS-negative pituitary adenoma showing neither significant cellular nor nuclear pleomorphism. Immunohistochemistry (streptavidin-biotin-peroxidase complex method) demonstrated cytoplasmic immunopositivity for LH in unevenly scattered adenoma cells. Stains for GH, PRL, ACTH, TSH, FSH and alpha subunit were negative. The Ki-67 nuclear labeling index was estimated at 2-6% (Figure 1), suggesting low cell proliferation rate. One slide was immunostained for O⁶ Methylguanine-DNA Methyl-Transferase (MGMT) (Figure 2). The results showed low immunopositivity (approximately 30 percent of the nuclei of the tumor cells, (a specimen from first surgery) and intermediate immunopositivity (more than 50 percent of the nuclei of the tumor cells, (a specimen from second surgery)).




Figure 1. Ki-67 nuclear labeling index showing immunopositive nuclei. Immunostaining for Ki-67 antigen. Magnification: 200x.




Figure 2. Immunostaining for MGMT. Several tumor cell nuclei are immunopositive for MGMT. Magnification: 400x.

Electron microscopy revealed a markedly oncocytic pituitary adenoma consisting of closely apposed, medium-size, somewhat round cells. Rough endoplasmic reticulum (RER) was scant and the collapsed sacculi of the Golgi complexes reflected low hormonal activity. The minute (50-100 nm), barely visible, peripherally disposed secretory granules exhibited very low electron density. Diffuse, advanced oncocytic change was apparent throughout the specimen. A diagnosis of oncocytic pituitary adenoma with gonadotroph differentiation, based largely upon LH immunoreactivity, was made.

In 2007, the patient complained of visual disturbance. Magnetic resonance imaging (MRI) showed regrowth of the tumor (3 cm x 3 cm) with sellar expansion, and both suprasellar extension as well as chiasmal compression (Figures 3A). Temozolomide therapy was begun (200 mg/day, orally for 5 days every 28 days). After five cycles, MRI disclosed significant changes with a minor reduction in tumor volume and an area of intratumoral necrosis (Figure 3B). One month later, the patient developed severe diarrhea and dehydration, followed by sudden cardiopulmonary collapse. A diagnosis of massive pulmonary embolism was made. The patient died and no autopsy was performed.

DISCUSSION

Oncocytic tumors are characterized by their cy-




Figure 3. Coronal, T1-weighted MRI with gadolinium enhancement shows a sellar and suprasellar tumor with chiasmal compression (3A). Coronal, T1-weighted MRI with gadolinium enhancement shows a spherical, hypointense, intratumoral area indicating involution of the tumor after five cycles of Temozolomide treatment (3B).

toplasmic abundance of mitochondria. They arise in several organs. Of those occurring in the pituitary, most consist of adenohypophysial cells and occur in older patients. As a rule, they are slow-growing benign adenomas, mostly macroadenomas, which displace and to a lesser extent invade surrounding tissues.^{13,14}

In our patient, MRI imaging showed tumor necrosis indicating responsiveness to Temozolomide therapy. MGMT is a DNA repair enzyme which removes alkyl adducts from DNA and counteracts the effects of Temozolomide upon tumor cells.¹⁵⁻²¹ Pituitary tumors which are MGMT immunonegative respond to treatment, whereas those that are MGMT im-

munopositive show no treatment response.¹⁷ Thus, immunohistochemical study of MGMT may predict responsiveness of the tumor cells to Temozolomide. In our case, groups of tumor cells were MGMT immunopositive, whereas others were immunonegative. It is noteworthy that many pituitary tumors diagnosed as null cell adenoma or gonadotrophic adenoma, either of which may be oncoytic, display variable degrees of differentiation in different areas of the same tumor resulting in variation, both in terms of morphology as well as in MGMT immunoreactivity and potential therapeutic responsiveness.¹⁴ Pituitary tumors composed of both MGMT immunopositive and immunonegative cells have also been reported by Widhalm et al.¹¹ Despite variation in MGMT expression in the present tumor, MRI indicated a certain degree of response. At present, the question of whether only the MGMT immunonegative cells responded and whether immunopositive cells were also affected by Temozolomide cannot be answered.

ACKNOWLEDGMENTS

The authors wish to thank the Jarislowsky and the Carr-Lloyd Harris Foundations as well as Mr. Jesus Rodriguez for their generous support.

REFERENCES

1. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C, 1997 Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. *Cancer Treat Rev* 23: 35-61.
2. Agarwala SS, Kirkwood JM, 2000 Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. *Oncologist* 5: 144-151.
3. Stupp R, Gander M, Leyvraz S, Newlands E, 2001 Current and future developments in the use of temozolomide for the treatment of brain tumours. *Lancet Oncol* 2: 552-560.
4. Kulke MH, Stuart K, Enzinger PC, et al, 2006 Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. *J Clin Oncol* 24: 401-406.
5. Fadul CE, Kominsky AL, Meyer LP, et al, 2006 Long-term response of pituitary carcinoma to temozolomide. Report of two cases. *J Neurosurg* 105: 621-626.
6. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP, 2006 Temozolomide: A novel treatment for pituitary carcinoma. *Lancet Oncol* 7: 518-520.

7. Syro LV, Uribe H, Penagos LC, et al, 2006 Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. *Clin Endocrinol (Oxf)* 65: 552-553.
8. Kovacs K, Horvath E, Syro LV, et al, 2007 Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. *Hum Pathol* 38: 185-189.
9. Neff LM, Weil M, Cole A, et al, 2007 Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. *Pituitary* 10: 81-86.
10. Moyes VJ, Alusi G, Sabin HI, et al, 2009 Treatment of Nelson's syndrome with temozolomide. *Eur J Endocrinol* 160: 115-119.
11. Widhalm G, Wolfsberger S, Preusser M, et al, 2009 O(6)-methylguanine DNA methyltransferase immunorexpression in nonfunctioning pituitary adenomas: Are progressive tumors potential candidates for temozolomide treatment? *Cancer* 115: 1070-1080.
12. Horvath E, Vidal S, Syro LV, Kovacs K, Smyth HS, Uribe H, 2001 Severe lymphocytic adenohypophysitis with selective disappearance of prolactin cells: A histologic, ultrastructural and immunoelectron microscopic study. *Acta Neuropathol* 101: 631-637.
13. Horvath E, Kovacs K, 1998 The adenohypophysis. In: Kovacs K, Asa SL (eds): *Functional endocrine pathology*, ed 2nd Malden, Blackwell; pp, 247-281.
14. Horvath E, Scheithauer BW, Kovacs K, Lloyd RV, 2002 Hypothalamus and pituitary. In: Graham DI, Lantos PL (eds): *Greenfield's neuropathology*, ed 7th New York, NY, Arnold Publishers, vol 1, pp, 983-1051.
15. Esteller M, Garcia-Foncillas J, Andion E, et al, 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. *N Engl J Med* 343: 1350-1354.
16. Hegi ME, Diserens AC, Godard S, et al, 2004 Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. *Clin Cancer Res* 10: 1871-1874.
17. Hegi ME, Diserens AC, Gorlia T, et al, 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 352: 997-1003.
18. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G 2005 Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. *Int J Cancer* 113: 379-385.
19. Pollack IF, Hamilton RL, Sobol RW, et al, 2006 O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: Results from the ccg-945 cohort. *J Clin Oncol* 24: 3431-3437.
20. Kovacs K, Scheithauer BW, Lombardero M, et al, 2008 MGMT immunorexpression predicts responsiveness of pituitary tumors to temozolomide therapy. *Acta Neuropathol* 115: 261-262.
21. McCormack AI, McDonald KL, Gill AJ, 2009 Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumors. *Clin Endocrinol (Oxf)* 71: 226-233.